OCUCLEAR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Ocuclear, and what generic alternatives are available?
Ocuclear is a drug marketed by Bayer Healthcare Llc and is included in one NDA.
The generic ingredient in OCUCLEAR is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.
Summary for OCUCLEAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 67 |
Patent Applications: | 1,937 |
Formulation / Manufacturing: | see details |
DailyMed Link: | OCUCLEAR at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for OCUCLEAR
US Patents and Regulatory Information for OCUCLEAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bayer Healthcare Llc | OCUCLEAR | oxymetazoline hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 018471-001 | May 30, 1986 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |